Ann Rehabil Med.  2012 Aug;36(4):578-583. 10.5535/arm.2012.36.4.578.

Rehabilitation for Ataxia Following Chemotherapy for Burkitt Lymphoma Involving the Rectum

• Kim HS
• Jung CO
• Jeon HR
• Sung LH

• KMID: 2266733
• DOI: http://doi.org/10.5535/arm.2012.36.4.578

Abstract

Burkitt lymphoma is a type of B-cell lymphoma that occurs mostly in children, and rarely in adults. The sporadic type is known to occur mostly at the ileum and cecum. Cytarabine, which is used for central nervous system prophylaxis during chemotherapy for Burkitt lymphoma, has known neurotoxicity, and its side effects include motor ataxia due to cerebellar injury, ataxic dysarthria, dysfunction of ocular movement, confusion, somnolence and lethargy. This case report is about a patient diagnosed with Burkitt lymphoma who manifested motor ataxia after chemotherapy that included cytarabine.

Keyword

Cytarabine; Cerebellar toxicity; Ataxia

MeSH Terms

Adult
Ataxia
Burkitt Lymphoma
Cecum
Central Nervous System
Child
Cytarabine
Dysarthria
Humans
Ileum
Lethargy
Lymphoma, B-Cell
Rectum
Cytarabine

Figure

• 

  Fig. 1 Brain MRI T2 Flair (2010. 10.28). There were no abnormal findings such as cortical atrophy or cerebromalatic changes in the cerebellum, but right sinusitis was observed.

• 

  Fig. 2 Brain PET CT (2010.10.29). Diffuse hypometabolism was observed in the bilateral frontal, parietal, temporal cortex areas and cerebellum.

• 

  Fig. 3 Brain PET CT (2011.2.25). Compared with a previous study, no interval change was observed (2010.10.29).

Reference

1. Aldoss IT, Weisenburger DD, Fu K, Chan WC, Vose JM, Bierman PJ, Bociek RG, Armitage JO. Adult Burkitt lymphoma: advances in diagnosis and treatment. Oncology (Williston Park). 2008; 22:1508–1517. PMID: 19133605.

2. Winkelman MD, Hines JD. Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study. Ann Neurol. 1983; 14:520–527. PMID: 6651239.

3. Hasle H. Cerebellar toxicity during cytarabine therapy associated with renal insufficiency. Cancer Chemother Pharmacol. 1990; 27:76–78. PMID: 2245495.

4. Lazarus HM, Herzig RH, Herzig GP, Phillips GL, Roessmann U, Fishman DJ. Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer. 1981; 48:2577–2582. PMID: 7306918.

5. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs. 2003; 63:1549–1563. PMID: 12887262.

6. Miller L, Link MP, Bologna S, Parker BR. Cerebellar atrophy caused by high-dose cytosine arabinoside: CT and MR findings. AJR Am J Roentgenol. 1989; 152:343–344. PMID: 2783512.

7. Nand S, Messmore HL Jr, Patel R, Fisher SG, Fisher RI. Neurotoxicity associated with systemic high-dose cytosine arabinoside. J Clin Oncol. 1986; 4:571–575. PMID: 3457102.

8. Donelli MG, Zucchetti M, Munzone E, D'Incalci M, Crosignani A. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer. 1998; 34:33–46. PMID: 9624235.